Skip to main content

Generic Briviact Availability

Last updated on Jan 11, 2023.

Briviact is a brand name of brivaracetam, approved by the FDA in the following formulation(s):

BRIVIACT (brivaracetam - solution;intravenous)

  • Manufacturer: UCB INC
    Approval date: May 12, 2016
    Strength(s): 50MG/5ML (10MG/ML) [RLD]

BRIVIACT (brivaracetam - solution;oral)

  • Manufacturer: UCB INC
    Approval date: May 12, 2016
    Strength(s): 10MG/ML [RLD]

BRIVIACT (brivaracetam - tablet;oral)

Has a generic version of Briviact been approved?

A generic version of Briviact has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Briviact and have been approved by the FDA:

brivaracetam tablet;oral

  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: January 6, 2023
    Strength(s): 50MG [AB], 100MG [AB]
  • Manufacturer: LUPIN LTD
    Approval date: December 20, 2022
    Strength(s): 10MG [AB], 25MG [AB], 50MG [AB], 75MG [AB], 100MG [AB]

Note: No generic formulation of the following products are available.

  • brivaracetam - solution;intravenous
  • brivaracetam - solution;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Briviact. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,729,653

    Patent expiration dates:

    • April 9, 2030
      ✓ 
      Drug product
  • 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
    Patent 6,911,461
    Issued: June 28, 2005
    Inventor(s): Differding; Edmond & Kenda; Benoît & Lallemand; Bénédicte & Matagne; Alain & Michel; Philippe & Pasau; Patrick & Talaga; Patrice
    Assignee(s): UCB, S.A.

    The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.

    Patent expiration dates:

    • February 21, 2026
      ✓ 
      Patent use: TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 21, 2026
      ✓ 
      Patent use: TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 21, 2026
      ✓ 
      Patent use: TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • August 27, 2024 - NEW PATIENT POPULATION

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.